

Genentech's Philosophy on Site-of-Care and Home Infusion

Background

Genentech recognizes that infusions of biologics are increasingly taking place in a variety of different settings: hospital outpatient departments, clinics, ambulatory infusion centers, and in the home. These dynamics have been driven by a variety of factors, including:

- Patient and/or provider preference
- Payer policies shifting infusion coverage to lower-cost settings
- COVID-19 related treatment setting shifts

In some instances, these changes may make it more difficult for providers and their patients to quickly find infusion sites that meet their needs for safety, quality, and accessibility.

At Genentech, we believe that providers and patients should be well-informed and be able to play a more active role in decisions surrounding the infusion process. That's why we have developed a philosophy on site-of-care and home infusion.

Our Philosophy

Genentech believes that treatment decisions, including the location of infusion, should be made between a patient and their provider based on the clinical assessment of the patient and the characteristics of the site-of-care.

Genentech believes that quality care can be achieved at different sites of infusion, provided that pharmacy and infusion staff are appropriately trained and patient care needs are addressed.*

Genentech believes all patients deserve timely access to clinically appropriate, affordable, and quality healthcare. This is best achieved when the patient and MS care team:

- Are informed of coverage and costs
- Are informed of site of infusion options
- Work together to make the best infusion site choice for the patient, based on the options available

Genentech continues to work with key stakeholders to create long-term sustainable solutions to help meet patient, provider, and payer needs.

*Administer OCREVUS® (ocrelizumab) under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions. Observe the patient for at least one hour after.

Our Commitment and Resources

Genentech is committed to providing beneficial resources for you and your patients. Your Genentech representative is available to answer your questions and provide additional information.

OCREVUS Patient Navigators provide assistance throughout the infusion process, from financial assistance options and insurance coverage to infusion location support and what to expect at an infusion.



**You can receive support from a Patient Navigator by calling
1-844-OCREVUS (627-3887)**

Genentech
A Member of the Roche Group